Tracking the in vivo release of bioactive NRG from @entity7050 and XXXX microparticles in infarcted hearts.

@entity37624 @entity7050 @entity35 @entity583 @entity73268 @entity968
UNASSIGNED: The growth factor neuregulin (NRG) is one of the most promising candidates in protein therapy as potential treatment for @entity583 ( @entity583 ). In the last few years, biomaterial based delivery systems, such as polymeric microparticles (MPs) made of @entity7050 and @entity968 ( @entity7050 and @entity73268 MPs), have improved the efficacy of protein therapy in preclinical studies. However, no cardiac treatment based on MPs has yet been commercialized since this is a relatively new field and total characterization of polymeric MPs remains mandatory before they reach the clinical arena. Therefore, the objective of this study was to characterize the in vivo release, bioactivity and biodegradation of @entity7050 and @entity73268 MPs loaded with biotinylated NRG in a @entity35 model of @entity583 . The effect of PEGylation in the clearance of the particles from the cardiac tissue was also evaluated. Interestingly, MPs were detected in the cardiac tissue for up to 12weeks after administration. In vivo release analysis showed that bNRG was released in a controlled manner throughout the twelve week study. Moreover, the biological cardiomyocyte receptor ( @entity37624 ) for NRG was detected in its activated form only in those animals treated with bNRG loaded MPs. On the other hand, the PEGylation strategy was effective in diminishing phagocytosis of these MPs compared to noncoated MPs in the long term (12weeks after injection). Taking all this together, we report new evidence in favor of the use of polymeric @entity7050 and @entity73268 MPs as delivery systems for treating @entity583 , which could be soon included in clinical trials.
